Balaji Amines Ltd
Balaji Amines Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹367 Cr, PAT ₹37 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaji Amines Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25 (Page 6, 5). Q1FY26 EBITDA: ₹64 crore, down from ₹74 crore in Q1FY25 (−14% YoY) - Q1FY26 EBITDA Margin: 17%, decreased from 19% in Q1FY25 - Q1FY26 Profit After Tax (PAT): ₹37 crore, down from ₹46 crore in Q1FY25 (−20% YoY) - Q1FY26 PAT Margin: 10%, down from 12% in Q1FY25 - No explicit margin outlook is stated in the presentation.
From Balaji Amines Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25 (Page 6, 5).
- Total volumes for Q1FY26: 27,570 MT, up from 25,871 MT in Q4FY25; YoY volume comparison not explicitly stated (Page 6).
- Segment volumes Q1FY26: Amines - 7,573 MT; Amines Derivatives - 8,108 MT; Specialty Chemicals - 11,889 MT (Page 6).
- Standalone revenue Q1FY26: ₹327 crore, flat quarter-on-quarter, down 3% YoY (Page 5).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit 4 Phase 2 & 3 Greenfield Capex at Subsidiary Plant to complete by FY26, including products like HCN, NaCN (30% solution, 100% solid), EDTA, Benzyl Cyanide, Phenylacetic Acid, TEOF/TMOF (Page 33, 25).
- Methylamines Plant expansion from 48,000 TPA to 88,000 TPA, commissioned Nov 10, 2024 (Page 9).
- Dimethyl Ether (DME) plant (1,00,000 TPA), under erection, to be commissioned FY25-26 (Page 9).
- N-Methyl Morpholine (NMM) facility (15 MT/day), under development, majority equipment procured, commissioning in FY25-26 (Page 9).
- Iso Propyl Amine plant (20-21 MT/day), modifications underway, commissioning post MPCB approval (Page 9).
- ACN plant technology upgrade and capacity increase, commissioning in FY26-27 (Page 9).
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines Ltd's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Chemicals & Petrochemicals this season
- Linde India Ltd (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key investor presentation takeaways from Linde
- Vidhi Specialty Food Ingredients Ltd (Q1 FY26)
87.9 Crores . Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 investor presentation — and how it ranks against sector pe
- Chemcon Speciality Chemicals Ltd (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key investor presentation takeaways from Chemcon Speciality Chemica
- Valiant Organics Ltd (Q1 FY26)
FY22: INR 1,153 Cr . Key investor presentation takeaways from Valiant Organics Ltd's Q1 FY26 investor presentation — and how it ranks against sector peers.
Frequently Asked Questions
What were Balaji Amines Ltd Q1 FY26 results?
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25 (Page 6, 5). Q1FY26 EBITDA: ₹64 crore, down from ₹74 crore in Q1FY25 (−14% YoY) - Q1FY26 EBITDA Margin: 17%, decreased from 19% in Q1FY25 - Q1FY26 Profit After Tax (PAT): ₹37 crore, down from ₹46 crore in Q1FY25 (−20% YoY) - Q1FY26 PAT Margin: 10%, down from 12% in Q1FY25 - No explicit margin outlook is stated in the presentation.
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Unit 4 Phase 2 & 3 Greenfield Capex at Subsidiary Plant to complete by FY26, including products like HCN, NaCN (30% solution, 100% solid), EDTA, Benzyl Cyanide, Phenylacetic Acid, TEOF/TMOF (Page 33, 25).
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.